Role of Combination Immunotherapy in Metastatic Renal Cell Carcinoma
Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.
Scenario 1: A 47-Year-Old Man With Intermediate Risk Metastatic RCC
Expert perspectives on a patient scenario of intermediate risk metastatic renal cell carcinoma and corresponding management with combination immunotherapy.
ASTRO/ESTRO Release Clinical Guideline for Local Therapy in Oligometastatic NSCLC
The American Society for Radiation Oncology and European Society for Radiotherapy & Oncology have released the first clinical guideline on the use of definitive local therapy, including radiation and surgery, for the treatment of patients with oligometastatic non–small cell lung cancer.
ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma
First-line consolidative autologous stem cell transplant following first complete remission, with or without maintenance rituximab, did not result in improved overall survival for patients with mantle cell lymphoma.